Cargando…
Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity
Anemia is a common complication of certain chronic diseases and can be treated by stimulating hematopoietic cells to increase red blood cell count, and this action is achieved by recombinant human erythropoietin. In this review article, we have discussed about hypertension, which develops as a resul...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894225/ https://www.ncbi.nlm.nih.gov/pubmed/33628672 http://dx.doi.org/10.7759/cureus.12804 |
_version_ | 1783653204095926272 |
---|---|
author | Brar, Simrandeep K Perveen, Sumera Chaudhry, Muhammad Reza AlBabtain, Sarah Amreen, Sana Khan, Safeera |
author_facet | Brar, Simrandeep K Perveen, Sumera Chaudhry, Muhammad Reza AlBabtain, Sarah Amreen, Sana Khan, Safeera |
author_sort | Brar, Simrandeep K |
collection | PubMed |
description | Anemia is a common complication of certain chronic diseases and can be treated by stimulating hematopoietic cells to increase red blood cell count, and this action is achieved by recombinant human erythropoietin. In this review article, we have discussed about hypertension, which develops as a result of erythropoietin therapy. We have explored the pathogenesis of erythropoietin-induced hypertension and discussed some ways to prevent and treat this condition. Also, an attempt has been made to find out the role of blood viscosity in erythropoietin-induced hypertension. We conducted a comprehensive review of literature by collecting data from online databases like PubMed and Google Scholar. We mainly studied clinical trials that unraveled the mechanism of hypertension caused by erythropoietin. Hypertension is mainly caused due to enhanced vascular responsiveness to constrictors and impaired action of vasodilators. Role of blood viscosity in the pathogenesis of hypertension is doubtful due to the lack of consistency in the studies. Incidence of hypertension can be reduced by achieving slow correction of anemia and by switching to subcutaneous route of administration. Conventional anti-hypertensives have been found to be beneficial in the treatment. In some severe and persistent cases, temporary discontinuation of erythropoietin may be needed. |
format | Online Article Text |
id | pubmed-7894225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-78942252021-02-23 Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity Brar, Simrandeep K Perveen, Sumera Chaudhry, Muhammad Reza AlBabtain, Sarah Amreen, Sana Khan, Safeera Cureus Internal Medicine Anemia is a common complication of certain chronic diseases and can be treated by stimulating hematopoietic cells to increase red blood cell count, and this action is achieved by recombinant human erythropoietin. In this review article, we have discussed about hypertension, which develops as a result of erythropoietin therapy. We have explored the pathogenesis of erythropoietin-induced hypertension and discussed some ways to prevent and treat this condition. Also, an attempt has been made to find out the role of blood viscosity in erythropoietin-induced hypertension. We conducted a comprehensive review of literature by collecting data from online databases like PubMed and Google Scholar. We mainly studied clinical trials that unraveled the mechanism of hypertension caused by erythropoietin. Hypertension is mainly caused due to enhanced vascular responsiveness to constrictors and impaired action of vasodilators. Role of blood viscosity in the pathogenesis of hypertension is doubtful due to the lack of consistency in the studies. Incidence of hypertension can be reduced by achieving slow correction of anemia and by switching to subcutaneous route of administration. Conventional anti-hypertensives have been found to be beneficial in the treatment. In some severe and persistent cases, temporary discontinuation of erythropoietin may be needed. Cureus 2021-01-20 /pmc/articles/PMC7894225/ /pubmed/33628672 http://dx.doi.org/10.7759/cureus.12804 Text en Copyright © 2021, Brar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Brar, Simrandeep K Perveen, Sumera Chaudhry, Muhammad Reza AlBabtain, Sarah Amreen, Sana Khan, Safeera Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title | Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title_full | Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title_fullStr | Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title_full_unstemmed | Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title_short | Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity |
title_sort | erythropoietin-induced hypertension: a review of pathogenesis, treatment, and role of blood viscosity |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894225/ https://www.ncbi.nlm.nih.gov/pubmed/33628672 http://dx.doi.org/10.7759/cureus.12804 |
work_keys_str_mv | AT brarsimrandeepk erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity AT perveensumera erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity AT chaudhrymuhammadreza erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity AT albabtainsarah erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity AT amreensana erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity AT khansafeera erythropoietininducedhypertensionareviewofpathogenesistreatmentandroleofbloodviscosity |